| Cas No.: | 136310-93-5 |
| SMILES: | O=C(C(C1=CC=CS1)(O)C2=CC=CS2)O[C@H]3C[C@H]([N+]4(C)C)[C@@H]5O[C@@H]5[C@H]4C3.[Br-] |
| Formula: | C19H22NO4S2.Br |
| M.Wt: | 472.42 |
| Purity: | >99% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel. |
| Target: | mAChR |
| In Vitro: | Tiotropium Bromide stops signaling between neurons and leads to muscle relaxation. Tiotropium Bromide is a long-acting, 24 hour, anticholinergic bronchodilator used in the management of chronic obstructive pulmonary disease. Tiotropium Bromide improves symptoms of chronic obstructive pulmonary disease complicated by chronic heart failure. |
| References: | [1]. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs. 2001 Apr;10(4):733-40. [2]. ZuWallack AR, ZuWallack RL. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Expert Opin Pharmacother. 2004 Aug;5(8):1827-35. [3]. Lipson DA. Tiotropium bromide. Int J Chron Obstruct Pulmon Dis. 2006;1(2):107-14. [4]. Mamary AJ, Criner GJ. Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2009 Jun;3(3):211-20. [5]. Szmidt M. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)]. Pneumonol Alergol Pol. 2012;80(3):255-62. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|